Gemcitabine 38 mg/mL (Gemcitabine INJECTION, SOLUTION) 38 mg/mL

Gemcitabine 38 mg/mL is an injectable solution used for various medical treatments. This intravenous medication is manufactured by Sagent Pharmaceuticals in the USA.

Strength

38 mg/mL

Pack Size

1 VIAL in 1 CARTON (25021-239-52) / 52.6 mL in 1 VIAL

Manufacturer / TM Owner

Sagent Pharmaceuticals

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Gemcitabine 38 mg/mL is primarily used in cancer treatment, often as part of a chemotherapy regimen. It works by interfering with the growth and spread of cancer cells. The specific uses of gemcitabine can vary, and it is typically administered by healthcare professionals in a clinical setting.

Side Effects

Common effects of gemcitabine may include fatigue, nausea, and a decreased appetite. Some individuals may also experience hair loss or changes in their blood cell counts. These effects can vary widely among patients.

Precautions & Warnings

Gemcitabine should be handled with care, as it is a potent medication. It is important to follow the instructions provided by healthcare professionals when administering this solution. Proper storage and disposal methods should be adhered to to ensure safety.

Avoid Interactions

Gemcitabine may interact with other medications, including certain chemotherapy drugs and radiation therapy. It is important to inform healthcare providers about all current medications and treatments before starting gemcitabine. Alcohol and other substances may also interact with gemcitabine, so caution is advised.

Frequently Asked Questions

Gemcitabine is primarily used in cancer treatment, often as part of a chemotherapy regimen.

Gemcitabine 38 mg/mL is administered intravenously by healthcare professionals in a clinical setting.

Common effects may include fatigue, nausea, and a decreased appetite. Some individuals may also experience hair loss.

Gemcitabine may interact with other medications, so it is important to inform healthcare providers about all current treatments.

Gemcitabine should be stored according to the instructions provided by the manufacturer to ensure its effectiveness and safety.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.